medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 2

<< Back Next >>

Ann Hepatol 2017; 16 (2)

Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience

Varghese J, Kumar KC, Venkataraman J, Srinivasan V, Deepashree T, Chinnappa UM, Ilankumaran K, Govil S, Srinivas RM, Rela M

Language: English
References: 23
Page: 247-254
PDF size: 220.95 Kb.


ABSTRACT

Background & Aim. Transarterial chemoembolization (TACE) or sorafenib is recommended for hepatocellular carcinoma BCLC stages B and C respectively. We studied the role of combination of TACE and sorafenib in BCLC stages B/C. Material and methods. We undertook an observational study on a cohort of cirrhotics with HCC from August 2010 through October 2014. Patients in BCLC stages B/C who had received TACE and/or sorafenib were included. mRECIST criteria were used to assess tumor response. The primary end point was overall survival. Results. Out of 124 patients, 47.6% were in BCLC-B and 52.4% in BCLCC. Baseline characteristics were comparable. The predominant etiology was cryptogenic (37.2% and 38.5%, p = NS). 49.1% in BCLC-B and 56.9% in BCLC-C had received TACE+sorafenib. In BCLC-B, the overall survival improved from 9 months (95% CI 6.3-11.7) using TACE only to 16 months (95% CI 12.9-19.1) using TACE+sorafenib (p ‹ 0.05). In BCLC-C, addition of TACE to sorafenib improved the overall survival from 4 months (95%CI 3-5) to 9 months (95%CI 6.8-11.2) (p ‹ 0.0001). As per mRECIST criteria, patients on TACE+sorafenib had reduced progressive disease (37.8% vs. 83.3%), improved partial response (43.2% vs. 3.3%) and one had complete response compared to those on sorafenib alone (p ‹ 0.0001) in BCLC-C but not in BCLC-B group. Hand foot syndrome was noted in 27.7% patients on sorafenib and post TACE syndrome in 80.2% patients, but both were reversible. No major adverse events were noted. Conclusion. TACE+sorafenib was more effective than TACE or sorafenib alone in HCC BCLC stages B or C with a significant survival benefit and improved tumour regression especially in BCLC-C patients.


REFERENCES

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.

  2. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010; 32: 344-55.

  3. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 2005; 5: 131-8.

  4. Llovet JM, Fuster J, Bruix J of the Barcelona-Clinic Liver Cancer Group. The Barcelona Approach: Diagnosis, Staging, and Treatment of Hepatocellular Carcinoma Liver Transplantation 2004; 10: S115-S120.

  5. Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol 2014; 20: 4115-27.

  6. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention- to-treat analysis. Hepatology 2008; 48: 819-27.

  7. Dong ZR, Zhang PF, Wang CH, Zhang C, Cai JB, Shi GM, Ke AW, et al. Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a retrospective analysis. Am J Cancer Res 2014; 5: 450-7.

  8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.

  9. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008; 103: 914-921.

  10. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase in hibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-40.

  11. Zhang L, Hu P and Bie P. Transarterial chemo-embolization (TACE) plus sorefanib versus TACE for Intermediate or Advanced Stage Hepatocellular carcinoma: A meta-analysis. PLoS ONE 2014; 9: e100305. doi: 10.1371/ journal.pone.0100305

  12. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Yang J et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3 randomised, double-blind, placebo controlled trial. Lancet Oncol 2015;16:1344-54.

  13. Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW, Lu DS. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 161-167.

  14. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.

  15. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: Available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-20.

  16. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-40.

  17. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Disease 2010; 30: 52.

  18. European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.

  19. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Brú C, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-7.

  20. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179-S188.

  21. Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, et al. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial. Future Oncol 2013; 9: 403-10.

  22. Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, et al. Interim analysis of START study: Study of Asia of the combination of TACE (transcatheter arterial chemoembolisation) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2013; 132: 2448-58.

  23. Hoffmann K, Ganten T, Gotthardtp D, Radeleff B, Settmacher U, Kollmar O, Nadalin S, et al. Impact of neo-adjuvant sorafenib treatment on liver transplantation in HCC patients- a prospective randomized double blind, phase III trial. BMC Cancer 2015; 15: 392. 24, Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, et al. Sorafenib or placebo plus TACE with doxorubicin- eluting beads for intermediate HCC: The SPACE trial. J Hepatol 2016; 64(5): 1090-8.




2020     |     www.medigraphic.com